Ulrike Setinek
Overview
Explore the profile of Ulrike Setinek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
401
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Illini O, Fabikan H, Hochmair M, Weinlinger C, Krenbek D, Brcic L, et al.
J Clin Med
. 2022 Jul;
11(14).
PMID: 35887862
About 15% of patients with non-small cell lung cancer (NSCLC) harbor the Kirsten rat sarcoma homolog G12C mutation (). Selective inhibitors offer new treatment opportunities, but little is known about...
2.
Holzknecht A, Illini O, Hochmair M, Krenbek D, Setinek U, Huemer F, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565374
Malignant pleural mesothelioma (MPM) is a rare pleural cancer associated with asbestos exposure. According to current evidence, the combination of chemotherapy, surgery and radiotherapy improves patients’ survival. However, the optimal...
3.
Buder A, Heitzer E, Waldispuhl-Geigl J, Weber S, Moser T, Hochmair M, et al.
Biomolecules
. 2021 Apr;
11(5).
PMID: 33919291
Background: To assess the clinical relevance of genome-wide somatic copy-number alterations (SCNAs) in plasma circulating tumor DNA (ctDNA) from advanced epidermal growth factor receptor ()-mutated lung adenocarcinoma patients. Methods: We...
4.
Papaporfyriou A, Domayer J, Meilinger M, Firlinger I, Funk G, Setinek U, et al.
Eur Respir Rev
. 2021 Jan;
30(159).
PMID: 33408086
Carcinoid tumours are rare neuroendocrine neoplasms that mostly occur in younger adults with low tendencies to metastasise. Based on their histological characteristics, they are divided into typical and atypical subtypes....
5.
Hochmair M, Fabikan H, Illini O, Weinlinger C, Setinek U, Krenbek D, et al.
Pharmaceuticals (Basel)
. 2020 Nov;
13(11).
PMID: 33171712
In clinical practice, patients with -rearrangement-positive non-small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors. The third-generation agent lorlatinib has been shown to inhibit a wide range...
6.
Buder A, Hochmair M, Setinek U, Pirker R, Filipits M
Transl Lung Cancer Res
. 2020 May;
9(2):239-245.
PMID: 32420063
Background: Osimertinib has become standard therapy of advanced epidermal growth factor receptor ()-mutated non-small cell lung cancer (NSCLC) patients and T790M-mediated resistance. We investigated the clinical utility of mutation tracking...
7.
Hochmair M, Setinek U, Krenbek D, Fazekas A, Illini O, Weinlinger C, et al.
Clin Lung Cancer
. 2019 Dec;
21(2):e49-e53.
PMID: 31879191
No abstract available.
8.
Hochmair M, Weinlinger C, Schwab S, Naber J, Setinek U, Krenbek D, et al.
Anticancer Drugs
. 2019 Jul;
30(7):e0787.
PMID: 31305295
The second-generation ALK tyrosine kinase inhibitor brigatinib has recently been approved in the European Union for use after crizotinib treatment in patients with EML4-ALK-rearranged lung cancer. In the current study,...
9.
Buder A, Setinek U, Hochmair M, Schwab S, Kirchbacher K, Keck A, et al.
Target Oncol
. 2019 Feb;
14(2):197-203.
PMID: 30810887
Background: Analysis of cell-free DNA from blood could provide an alternative method for identifying genomic changes in the tumors of patients with advanced lung adenocarcinoma. Objective: We compared the performance...
10.
Keppens C, Palma J, Das P, Scudder S, Wen W, Normanno N, et al.
J Mol Diagn
. 2018 Apr;
20(4):483-494.
PMID: 29704571
Molecular testing of EGFR is required to predict the response likelihood to targeted therapy in non-small cell lung cancer. Analysis of circulating tumor DNA in plasma may complement limitations of...